![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
Advertisement
All
>
Persons > Northern Europe
Please find below persons from Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden and the UK as well as related to organisations from these countries.Total search results: 4148 | Ordered by Person (ascending)
1 2 3 ... 28 29 30 ... 40 41 42 
  Person |
 Position |
Organisation (Group) |
Country |
|---|---|---|---|
| Oinonen, Tero (4Pharma 202306 CEO) | Chief Executive Officer (CEO) | BC Platforms (BCP) (Group) | Finland |
| Olafsson, Sigurdur Oli (Teva 201407– CEO of Global Generic Medicines business before Actavis CEO) | Chief Executive Officer (CEO) | Teva (Group) | Israel |
| Olander, Kristina Windrup (Spikinc AB 202110) | Public Relations Manager / Investor Relations Manager | Spikinc AB | Sweden |
| Oldfield, Steve (Teva 201506– General Manager UK +IE before Sanofi Managing Director UK+IE) | General Manager (management) | Teva (Group) | United Kingdom (GB) |
| Olesen, Claus Elsborg (STipe Therapeutics 201909 CEO) | Chief Executive Officer (CEO) | STipe Therapeutics (DK) | Denmark |
| Olesen, Palle Holm (Lundbeck 201309 Head of Investor Relations) | Public Relations Manager / Investor Relations Manager | Lundbeck (Group) | Denmark |
| Olesen, Thea (BioPorto 2000–20107 CEO RESIGNED 7/13) | Chief Executive Officer (CEO) | BioPorto (Group) | Denmark |
| Oliff, Allen (GSK 200612 SVP Molecular Discovery Research) | n. a. | GSK (Group) | United Kingdom (GB) |
| Olin, Martin (Symphogen 201609– CEO before CFO since 201204 before SLS Invest + Novo Nordisk) | Chief Executive Officer (CEO) | Servier (Group) | Denmark |
| Olin, Thomas (Kancera 2010– CEO + Co-founder before iNovacia 200605– CEO) | Chief Executive Officer (CEO) | Kancera AB | Sweden |
| Olivecrona, Hans (PCI Biotech 201708– CMO before Swedish Orphan Biovitrum) | Chief Medical Officer (CMO) | PCI Biotech (Group) | Norway |
| Oliver, Paul (BioCity (GB) 201511– CFO before Vectura Group plc) | Chief Financial Officer (CFO) | Pioneer Group, The (WAPG) (Group) | United Kingdom (GB) |
| Ollier, Michèle (Medixci Ventures 201602– General Partner before Index Ventures + Funxional Therapeutics) | General Partner (venture partner) | Medicxi Ventures (formerly Index Ventures Life Sciences) | United Kingdom (GB) |
| Olsen, Jan (Clarmon Corp 200811 COO) | Chief Operating Officer (COO) | Clarmon Corporation | United Kingdom (GB) |
| Olsen, Jesper Velgaard (Univ Copenhagen 201404– Professor + Vice Director of NNF-CPR joined 5/09 before MPI) | Professor | Max Planck Society for the Advancement of Science | Germany |
| Olsen, John (Hogarth Partnership 200407) | n. a. | Hogarth Partnership | United Kingdom (GB) |
| Olsson, Fredrik (Genovis 201906 CEO) | Chief Executive Officer (CEO) | Genovis (Group) | Sweden |
| Olsson, Lina (HiloProbe 202305 CEO) | Chief Executive Officer (CEO) | HiloProbe AB | Sweden |
| Opdam, Frank (Qnostics 201802 Head of Commercial) | Chief Commercial Officer (CCO) | Qnostics (Group) | United Kingdom (GB) |
| Oppitz, Norbert (Swedish Orphan Biovitrum 201710– SVP Specialty Care before BSN Medical + Endo + Takeda/Nycomed + Roche) | President/Director/Head Business Group/Unit/Division | Swedish Orphan Biovitrum (Sobi) (Group) | Sweden |
| Orda, Mina (Sachs Associates 20140124 Event Manager) | Event Manager / Conference Manager | Sachs Associates Ltd. | United Kingdom (GB) |
| Oredsson, Michael (BioInvent 201310 CEO before CEO at Probi AB before Pharmacia) | Chief Executive Officer (CEO) | BioInvent International AB (Nasdaq Stockholm: BINV) | Sweden |
| Orville, Jake (NextGen 200611– VP Global Sales) | n. a. | NextGen (Group) | United Kingdom (GB) |
| Osborne, Angela (eXmoor Pharma 202302 CEO) | Chief Executive Officer (CEO) | eXmoor Pharma Concepts Ltd. | United Kingdom (GB) |
| Osborne, Stephen (Pastel BioScience 201509 CEO + CSO + Founder) | Chief Executive Officer (CEO) | Pastel BioScience Ldt. | United Kingdom (GB) |
| Osbourn, Jane (Alchemab Therapeutics 202104 CSO + Co-Founder formerly BIA 201710 Board Chairman) | Chief Scientific Officer (CSO) / Chief Development Officer (CDO) | Alchemab Therapeutics Ltd. | United Kingdom (GB) |
| Osherovich, Lev (Delin Ventures 202210 Partner) | Partner (venture partner) | Delin Ventures (GB) | United Kingdom (GB) |
| Osing, Jurgen (Deerac Fluidics 200805 Managing Director) | Managing Director | Allegro Technologies (Deerac) (Group) | Ireland, Republic of |
| Osswald, Gunilla (BioArctic 201805 CEO) | Chief Executive Officer (CEO) | BioArctic AB (Nasdaq Stockolm: BIOAB) | Sweden |
| Ouberai, Myriam M. (Speria 201510– CEO + Founder) | Chief Executive Officer (CEO) | Spirea Ltd. | United Kingdom (GB) |
| Overton, Paul (Sygnature Discovery 202307 Chief Commercial Officer) | Chief Commercial Officer (CCO) | Sygnature Discovery (Group) | United Kingdom (GB) |
| Owen, Alison (Scott Partnership 202110) | Public Relations Manager / Investor Relations Manager | Scott Partnership (Scott PR) (Group) | United Kingdom (GB) |
| Owen, David (200510– Board Non-Exec OGT) | Board member, non-executive | Sysmex (Group) | United Kingdom (GB) |
| Owen, Mike (Kymab 201007 CSO before GSK 200612 SVP Biopharmaceuticals CEDD) | Chief Scientific Officer (CSO) / Chief Development Officer (CDO) | Sanofi (Group) [since May 2011] | United Kingdom (GB) |
| Owens, Anthony (Arran Chemical 201511 Managing Director) | Managing Director | Almac (Group) | Ireland, Republic of |
| Oxlade, David (Xenova 200504 CEO) | Chief Executive Officer (CEO) | Auven Therapeutics (Group) | United Kingdom (GB) |
| O’Brien, Patrick (Capital Cell 201810 Investment Manager) | Investment Manager | Capital Cell (GB) | United Kingdom (GB) |
| O’Brien, Patrick (MedCity London 201611 Performance + Projects Manager) | Business Development Manager / Strategy Manager | MedCity (London) | United Kingdom (GB) |
| O’Brien, Shikha (Congenica 201701– CBO based in San Diego before Dotmatics VP Strategic Sales + Marketing) | Sales Manager / Marketing Manager | Insightful Science (Group) | United Kingdom (GB) |
| O’Brien, Vincent (Sistemic 201202 CSO) | Chief Scientific Officer (CSO) / Chief Development Officer (CDO) | Sistemic Ltd. | United Kingdom (GB) |
| O’Bryan-Tear, Gillies (Algeta 201112 CMO) | Chief Medical Officer (CMO) | Bayer (Group) | Norway |
| O’Connell, Alan (Seroba Life Sciences 201702 Partner joined 2003 before Elan Corp + American Biogenetic Sciences) | Partner (venture partner) | Seroba (Group) | Ireland, Republic of |
| O’Connell, Daniel (Arix Bioscience 201706 Investment Manager) | Investment Manager | Arix Bioscience (Group) | United Kingdom (GB) |
| O’Connell, John (InforSense 200508– Board Director) | n. a. | Danaher (Group) | United Kingdom (GB) |
| O’Connor, Chris (Techcomp 201309 CEO of Techcomp Europe before Barloworld Scientific CEO) | Chief Executive Officer (CEO) | Techcomp (Group) | United Kingdom (GB) |
| O’Connor, Peter (Univ Warwick 201204 Professor) | Professor | University of Warwick | United Kingdom (GB) |
| O’Donovan, Kevin (Evogen Ltd 200608 Chairman before Co-Founder Hybaid Ltd) | n. a. | Evogen (Group) | United Kingdom (GB) |
| O’Dwyer, Terence (Terry) (LSX 202204 CEO + Co-Founder) | Chief Executive Officer (CEO) | Informa (Group) [NEW] | United Kingdom (GB) |
| O’Halloran, Jonathan (QuantuMDx 201409 inventor of Q-POC device) | n. a. | QuantuMDx (Group) | United Kingdom (GB) |
| O’Hara, Stephen (OptiBiotix 201703 CEO) | Chief Executive Officer (CEO) | OptiBiotix Health (Group) | United Kingdom (GB) |
| O’Higgins, John (Spectris 201801 CEO) | Chief Executive Officer (CEO) | Spectris (Group) | United Kingdom (GB) |
| O’Leary, Kevin (Qumas 201312 CEO) | Chief Executive Officer (CEO) | Dassault Systèmes (3DS) (Group) | Ireland, Republic of |
| O’Lionaird, Eoghan (Spectris 201611 Business Group Director of Materials Analysis segment) | President/Director/Head Business Group/Unit/Division | Spectris (Group) | United Kingdom (GB) |
| O’Meara, Jack (Ochre Bio 202106 CEO + Co-Founder) | Chief Executive Officer (CEO) | Ochre Bio Ltd. | United Kingdom (GB) |
| O’Neil, Deborah (NovaBiotics 202010 CEO) | Chief Executive Officer (CEO) | NovaBiotics (Group) | United Kingdom (GB) |
| O’Neill, Catherine (SkinBioTherapeutics plc 201704 CEO) | Chief Executive Officer (CEO) | SkinBioTherapeutics plc (AIM: SBTX) | United Kingdom (GB) |
| O’Neill, Jim (United Kingdom (govt) 201607 UK Commercial Secretary to the Treasury before Goldman Sachs) | Administrative Officer (personnel) | United Kingdom (GB) (govt) | United Kingdom (GB) |
| O’Neill, Luke (Trinity College Dublin 201905 Prof + Chair of Biochemistry + SAB Member of Kintai Therapeutics) | Professor | Trinity College Dublin | Ireland, Republic of |
| O’Riordan, Paul (Synexa Life Sciences 202205 Chairman) | Board member, non-executive | Synexa Life Sciences (Group) | Finland |
| O’Sullivan, Euan (LGC 201212 Managing Director of LGC Standards) | Managing Director | LGC (Group) | United Kingdom (GB) |
| Pagano, Anthony (Genmab 202003– CFO before SVP Finance + CorpDev since 2011 joined 2007) | Chief Financial Officer (CFO) | Genmab (Group) | Denmark |
| Page, Andy (Beckley Psytech 202102– COO before Otsuka Pharmaceutical Europe + Janssen UK + SKB) | Chief Operating Officer (COO) | Beckley Psytech Ltd. | United Kingdom (GB) |
| Page, Brian (Labtech 200811 Managing Director) | Managing Director | Labtech International (Group) | United Kingdom (GB) |
| Painter, Alex-James (Univ Cambridge 200706) | n. a. | University of Cambridge | United Kingdom (GB) |
| Pairaudeau, Garry (Exscientia 202011–CTO before AstraZeneca) | Chief Technology/Technical Officer (CTO) | Exscientia (Group) | United Kingdom (GB) |
| Palenius, Tom (Abacus Diagnostica 201208 Managing Director) | Managing Director | Abacus Diagnostica Oy | Finland |
| Palm, Henrik (Karo Bio 201110– CFO) | Chief Financial Officer (CFO) | Karo Healthcare (Group) | Sweden |
| Palmer, Daniel (Q Chip 200712 Collaborative Research Manager) | Research & Development Manager | Q Chip (Group) | United Kingdom (GB) |
| Paloheimo, Lea (Biohit 202209 Board Chair) | Board member, non-executive | Biohit (Group) | Finland |
| Palotie, Aarno (Univ Helsinki 202002 Prof + Research Director of FIMM + Head of FinnGen) | Professor | University of Helsinki | Finland |
| Palu, Michel (Norlab 201108 Managing Director + founder in 1992) | Managing Director | Norlab (Group) | Finland |
| Pammenter-Fry, Ellen (Zyme Communications 201409– Account Executive) | Public Relations Manager / Investor Relations Manager | Zyme Communications Ltd. | United Kingdom (GB) |
| Panagos, Costa (Quintiles 201505 SVP + Global Head of Global Central Laboratories) | President/Director/Head Business Group/Unit/Division | Iqvia (Group) | United Kingdom (GB) |
| Pangalos, Menelas (AstraZeneca 201303 EVP Innovative Medicines + Early Development Biotech Unit) | President/Director/Head Business Group/Unit/Division | AstraZeneca (Group) | United Kingdom (GB) |
| Pankhania, Jayesh (Congenica 202104– CFO before Horizon DIscovery + Xtera + HOC Group + Asia Resource Minerals) | Chief Financial Officer (CFO) | Congenica (Group) | United Kingdom (GB) |
| Panter, Ben (Blackford Analysis 202301 CEO) | Chief Executive Officer (CEO) | Bayer (Group) | United Kingdom (GB) |
| Panting, Robert (Rentschler 202110– General Manager of Rentschler ATMP Ltd before Fujifilm Diosynth Biotechnologies) | General Manager (management) | Rentschler (Group) | United Kingdom (GB) |
| Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK) | Chief Executive Officer (CEO) | Takeda (Group) | United Kingdom (GB) |
| Papadakis, Michalis (Brainomix 201804 CEO + Co-Founder) | Chief Executive Officer (CEO) | Brainomix Ltd. | United Kingdom (GB) |
| Pappas, Arthur (AM Pappas 1994– Managing Parntner + Founder before GSK) | Managing Partner (investment firm) | A. M. Pappas & Associates (Pappas Capital / Pappas Ventures) | United States (USA) |
| Paqueville, Frédéric (Excelya 202010 Executive President + Co-Founder) | President/Director/Head Business Group/Unit/Division | Excelya (Group) | France |
| Parfrey, Jo (Babraham Institute 201907 Non-executive Director of Babraham Bioscience Technologies Ltd) | Board member, non-executive | Babraham Institute | United Kingdom (GB) |
| Parini, Michael (Freeline Therapeutics 202311 CEO) | Chief Executive Officer (CEO) | Freeline Therapeutics Holdings plc (FRLN) | United Kingdom (GB) |
| Parker, Alan (Univ Cardiff 2013– Prof at School of Medicine + Accession Therapeutics 202211– CSO of Trocept Tx) | Professor | University of Cardiff School of Medicine | United Kingdom (GB) |
| Parker, Peter (Piramed 200605 Co-founder) | Company Founder | Roche (Group) | United Kingdom (GB) |
| Parker, Stephen (Physiomics 200507 Chairman) | Board member, non-executive | Physiomics plc (AIM: PYC) | United Kingdom (GB) |
| Parkhill, Julian (Sanger Institute 200812 Director of Sequencing) | n. a. | Wellcome Trust, The | United Kingdom (GB) |
| Parkhouse, Chris (Deyton Bell 2005– Managing Director + Founder) | Managing Director | Deyton Bell Ltd. | United Kingdom (GB) |
| Parkin, Glyn (Actimed Therapeutics –201910 initial CEO RETIRED 10/19 continues as advisor) | Chief Executive Officer (CEO) | Actimed Therapeutics Ltd. | United Kingdom (GB) |
| Parks, Diane (Kite Pharma + Amgen + Phamracyclics) | Board member, non-executive | Calliditas Therapeutics (Group) | Sweden |
| Parnell, Geoff (Delta Precision 202301 Managing Director + Co-Founder) | Managing Director | Biotage (Group) | United Kingdom (GB) |
| Parr, David (Biochrom Group 200612 Managing Director) | Managing Director | Harvard Bioscience (Group) | United Kingdom (GB) |
| Parrett, William G. (Deloite Touche –2007 retired) | n. a. | Deloitte Touche Tohmatsu (Group) | United Kingdom (GB) |
| Parry, Charlotte (Arix Bioscience 201804 Investor Relations Manager) | Public Relations Manager / Investor Relations Manager | Arix Bioscience (Group) | United Kingdom (GB) |
| Parry, David M. (Cyclofluidic 201102 COO) | Chief Operating Officer (COO) | Pfizer (Group) | United Kingdom (GB) |
| Pasanen, Olli (Euformatics 201709 CEO) | Chief Executive Officer (CEO) | Euformatics Oy | Finland |
| Pasteur, Alexander (Alex) (F-Prime Capital Partners 202110 Partner) | Investment Manager | F-Prime Capital Partners (F-Prime Biosciences) | United Kingdom (GB) |
| Patel, Ashish (Ash) (UnitedHealth 202002 Principal at Optum Ventures before Mercia Technologies) | Investment Manager | UnitedHealth (Group) | United Kingdom (GB) |
| Patel, Nikin (Molecular Profiles 201208 CEO) | Chief Executive Officer (CEO) | Columbia Laboratories (Group) | United Kingdom (GB) |
| Patel, Nirmesh (Cambridge Cancer Genomics 201903 CSO) | Chief Scientific Officer (CSO) / Chief Development Officer (CDO) | Dante Genomics (Group) | United Kingdom (GB) |
1 2 3 ... 28 29 30 ... 40 41 42
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
